Immucell (ICCC) EBITDA Margin (2010 - 2026)
Immucell (ICCC) posted EBITDA Margin of 33.48% for Q2 2026, up 14.03 percentage points from 19.45% a year earlier.
Powered by 
Analysis
Immucell (ICCC) EBITDA Margin (2010 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Immucell was 18.86%, up 2.99 percentage points year-over-year; for FY2025, it came in at 16.11%, up 11.92 percentage points from FY2024.
- Annual EBITDA Margin shows a five-year change of +9.01 percentage points (FY2020 to FY2025).
- In prior years, Immucell's EBITDA Margin was 4.19% in FY2024 (+21.29 pp), -17.11% in FY2023 (-18.27 pp), 1.16% in FY2022 (-13.11 pp) and 14.27% in FY2021 (+7.17 pp).
- The Q2 2026 figure stands as the highest quarterly EBITDA Margin in data going back to Q3 2010.
- On a year-over-year basis, EBITDA Margin increased in five of the last six quarters, with an average year-over-year change of +12.86 percentage points.
- The strongest year-over-year quarter for EBITDA Margin in the past five years was Q1 2024, with a gain of 51.47 percentage points; the weakest was Q1 2023, with a drop of 66.19 percentage points.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 39.16% |
| 10 | Immucell | 94.27 Mn | 71.72 Mn | 2.44 Mn | 33.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.52% |
| Dec 31, 2025 | 8.65% |
| Sep 30, 2025 | 13.86% |
| Jun 30, 2025 | 19.62% |
| Mar 31, 2025 | 22.56% |
| Dec 31, 2024 | 17.05% |
| Sep 30, 2024 | 2.11% |
| Jun 30, 2024 | -12.59% |
| Mar 31, 2024 | 5.41% |
| Sep 30, 2023 | -8.55% |
| Jun 30, 2023 | -17.30% |
| Mar 31, 2023 | -46.15% |
| Dec 31, 2022 | -26.10% |
| Sep 30, 2022 | 0.50% |
| Jun 30, 2022 | 0.49% |
| Mar 31, 2022 | 19.98% |
| Dec 31, 2021 | 13.84% |
| Sep 30, 2021 | 17.40% |
| Jun 30, 2021 | 18.59% |
| Mar 31, 2021 | 6.13% |
API Access
Immucell EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ICCC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "ICCC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ICCC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();